Interleukin 10 Cytokine Synthesis Inhibitory Factor or CISF or IL10-Pipeline Review, H1 2016

Interleukin 10 Cytokine Synthesis Inhibitory Factor or CISF or IL10-Pipeline Review, H1 2016


  • Products Id :- GMDHC0122TDB
  • |
  • Pages: 75
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)-Pipeline Review, H1 2016', provides in depth analysis on Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)

The report reviews Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Overview 8

Therapeutics Development 9

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)-Products under Development by Stage of Development 9

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)-Products under Development by Therapy Area 10

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)-Products under Development by Indication 11

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)-Pipeline Products Glance 13

Late Stage Products 13

Early Stage Products 14

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)-Products under Development by Companies 15

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)-Products under Development by Universities/Institutes 18

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)-Therapeutics Assessment 20

Assessment by Monotherapy/Combination Products 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)-Companies Involved in Therapeutics Development 27

BioMAS Ltd. 27

Biotest AG 28

enGene, Inc 29

Intrexon Corporation 30

LEO Pharma A/S 31

Merck & Co., Inc. 32

P2D Bioscience 33

Pfizer Inc. 34

SK Biopharmaceuticals Co., Ltd. 35

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)-Drug Profiles 36

AM-0010-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

ANV-103-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

AS-101-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Biologic to Activate Glutamic Acid Decarboxylase and IL-10 for Type 1 Diabetes-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Biologic to Target Gluten and IL-10 for Celiac Disease-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Biologic to Target Insulin Receptor and IL-10 for Type 1 Diabetes-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

BT-063-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Cell Therapy to Activate IL-10 for Autoimmune Myocarditis and Inflammation-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Dekavil-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

EG-10-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

EG-12-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Elmyelin-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Gene Therapy to Activate Interleukin 10 for Atherosclerosis-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Gene Therapy to Activate Interleukin-10 for ALS-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

LEO-32731-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

MK-1966-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

PD-2244-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

SKL-16036-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Synthetic Peptides to Inhibit IL-10 and IFN Gamma for Cancer, Viral Infections and Inflammatory Diseases-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

XT-101-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

XT-150-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)-Dormant Projects 61

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)-Discontinued Products 64

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)-Featured News & Press Releases 65

Jun 06, 2016: ARMO BioSciences AM0010 Demonstrates Promising Clinical Data as an Immuno-oncology Monotherapy and in Combination with an Anti-PD-1 Checkpoint Inhibitor in Advanced Solid Tumors, Including Immune-Resistant Cancers 65

Apr 20, 2016: ARMO BioSciences Announces AM0010 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting in June 2016 66

Mar 31, 2016: Xalud Therapeutics Discovers Potential Solution for Opioid Abuse Crisis 67

Mar 16, 2016: ARMO BioSciences to Present New Clinical Trial Results for AM0010 at Upcoming Medical Conferences 68

Jan 08, 2016: ARMO BioSciences to Present at the 34th Annual J.P. Morgan HealthCare Conference 68

Oct 30, 2015: ARMO BioSciences Presents Positive Phase 1 Trial Results of AM0010 at Upcoming Medical Conferences 69

Oct 06, 2015: Biotest reaches the next milestone in the clinical development of its monoclonal antibody BT-063 by starting the clinical phase IIa trial in the indication systemic lupus erythematosus 69

Jun 01, 2015: ARMO BioSciences Announces Efficacy and Safety Data for Immuno-Oncology Program with Novel Mechanism of Action 70

May 13, 2015: ARMO BioSciences Announces Presentation on Promising Immuno-Oncology Program at 2015 ASCO Annual Meeting 71

Jun 23, 2014: Cytovance Biologics selected for GMP manufacture of AM0010 for ARMO BioSciences 71

Nov 25, 2013: ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy 72

Apr 11, 2012: University Of Leuven And ActoGeniX Announce Study Results Of ActoBiotic In Treatment Of Type 1 Diabetes 72

Sep 30, 2009: Biotest AG Announces Initiation of Clinical development of BT-063 73

Appendix 74

Methodology 74

Coverage 74

Secondary Research 74

Primary Research 74

Expert Panel Validation 74

Contact Us 74

Disclaimer 75

List of Figures

Number of Products under Development for, H1 2016 9

Number of Products under Development by Therapy Area, H1 2016 10

Number of Products under Development by Top 10 Indication, H1 2016 11

Comparative Analysis by Early Stage Products, H1 2016 14

Assessment by Monotherapy/Combination Products, H1 2016 20

Number of Products by Mechanism of Actions, H1 2016 21

Number of Products by Stage and Mechanism of Actions, H1 2016 21

Number of Products by Routes of Administration, H1 2016 23

Number of Products by Stage and Routes of Administration, H1 2016 23

Number of Products by Molecule Types, H1 2016 25

Number of Products by Stage and Molecule Type, H1 2016 25

List of Tables

Number of Products under Development for, H1 2016 9

Number of Products under Development by Therapy Area, H1 2016 10

Number of Products under Development by Indication, H1 2016 11

Comparative Analysis by Late Stage Development, H1 2016 13

Comparative Analysis by Early Stage Products, H1 2016 14

Number of Products under Development by Companies, H1 2016 15

Products under Development by Companies, H1 2016 16

Products under Development by Companies, H1 2016 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H1 2016 18

Products under Investigation by Universities/Institutes, H1 2016 19

Assessment by Monotherapy/Combination Products, H1 2016 20

Number of Products by Stage and Mechanism of Action, H1 2016 22

Number of Products by Stage and Route of Administration, H1 2016 24

Number of Products by Stage and Molecule Type, H1 2016 26

Pipeline by BioMAS Ltd., H1 2016 27

Pipeline by Biotest AG, H1 2016 28

Pipeline by enGene, Inc, H1 2016 29

Pipeline by Intrexon Corporation, H1 2016 30

Pipeline by LEO Pharma A/S, H1 2016 31

Pipeline by Merck & Co., Inc., H1 2016 32

Pipeline by P2D Bioscience, H1 2016 33

Pipeline by Pfizer Inc., H1 2016 34

Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 35

Dormant Projects, H1 2016 61

Dormant Projects (Contd..1), H1 2016 62

Dormant Projects (Contd..2), H1 2016 63

Discontinued Products, H1 2016 64

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

BioMAS Ltd.

Biotest AG

enGene, Inc

Intrexon Corporation

LEO Pharma A/S

Merck & Co., Inc.

P2D Bioscience

Pfizer Inc.

SK Biopharmaceuticals Co., Ltd.

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Therapeutic Products under Development, Key Players in Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Therapeutics, Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Pipeline Overview, Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Pipeline, Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Pipeline Assessment

select a license

Single User License
USD 3500 INR 225225
Site License
USD 7000 INR 450450
Corporate User License
USD 10500 INR 675675

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com